Menopause Diagnostic Algorithm: Step by Step

What Does "Menopause" Actually Mean Clinically?

Menopause is a single point in time, not a phase. It is defined retrospectively after 12 consecutive months without a menstrual period, with no other physiological or pathological cause The Menopause Society, 2023. The years of hormonal change leading up to that point are called perimenopause. The years after are post-menopause.

This distinction matters because treatment decisions, symptom burden, and cardiovascular or bone-health risk all shift depending on where you are in this continuum.

Three Distinct Stages You Need to Know

Perimenopause begins when your cycle becomes irregular, typically 4 to 10 years before your final period. Estrogen and progesterone fluctuate unpredictably rather than declining in a straight line. Hot flashes, disrupted sleep, and cycle irregularity are common but do not confirm menopause.

Menopause is confirmed on the one-year anniversary of your last period. The average age in the United States is 51 years, with a normal range of 45 to 55 years Harlow et al., 2012, Menopause.

Post-menopause is every day after that confirmed final period. Estrogen remains low and stable. Genitourinary syndrome of menopause (GSM), bone mineral density loss, and cardiovascular risk accumulate over this phase.

Step 1: Take a Full Menstrual and Symptom History

The first step in any menopause workup is a detailed menstrual history. No test replaces this.

Ask yourself, or your clinician will ask you, these core questions. When was your last period? Has your cycle length changed in the past two years? Are you experiencing vasomotor symptoms (hot flashes, night sweats)? Do you have vaginal dryness, pain with sex, or urinary urgency?

The STRAW+10 staging system classifies reproductive aging into nine stages from peak reproductive years through late post-menopause. Clinicians use it to place you on the continuum based on cycle variability and bleeding pattern alone. For most women between 45 and 55 with classic symptoms and a changing cycle, the history is sufficient to reach a working clinical diagnosis without any laboratory testing.

Symptoms That Support the Diagnosis

• Vasomotor symptoms (VMS): hot flashes and night sweats, reported by up to 75% of women in the menopausal transition
• Sleep disturbance disproportionate to mood or anxiety
• Irregular or heavier-than-usual periods before cessation
• Genitourinary symptoms: vaginal dryness, dyspareunia, recurrent urinary tract infections, urinary urgency
• Mood changes, cognitive fogginess, joint aches (less specific but frequently reported)

Symptoms That Should Trigger a Broader Workup

Postmenopausal bleeding (any bleeding after 12 months of amenorrhea) is endometrial cancer until proven otherwise. Refer for transvaginal ultrasound and endometrial sampling before attributing bleeding to hormonal fluctuation.

Step 2: Rule Out Other Causes of Amenorrhea

Before confirming menopause, you must exclude the following conditions. This step applies to any woman with secondary amenorrhea regardless of age.

Pregnancy. A urine or serum beta-hCG is the first test in any woman with amenorrhea who has had any potential for conception, including perimenopausal women. Spontaneous conception is possible well into perimenopause.

Thyroid dysfunction. Both hypothyroidism and hyperthyroidism can disrupt menstrual cycles and produce symptoms that overlap with menopause (fatigue, heat intolerance, mood change, weight shift). A TSH should be obtained in any woman with amenorrhea or significant VMS. Postpartum thyroiditis, which may go unrecognized, can cause a similar picture in recently postpartum women.

Hyperprolactinemia. Elevated prolactin suppresses GnRH and disrupts the hypothalamic-pituitary-ovarian axis. A serum prolactin level rules this out.

Hypothalamic amenorrhea. Low body weight, excessive exercise, or chronic psychological stress can suppress the HPO axis and produce estrogen levels and symptoms indistinguishable from menopause. FSH in this situation is typically low-normal, not elevated.

Primary adrenal insufficiency and other endocrine causes are less common but warrant consideration when the clinical picture is atypical.

ACOG Practice Bulletin No. 182 provides a framework for secondary amenorrhea evaluation; the specific menopause guidance is contained in ACOG Clinical Practice Bulletin on Menopause.

Step 3: Decide Whether Laboratory Testing Is Needed

For women between 45 and 55 with classic symptoms and an evolving cycle pattern, the 2023 Menopause Society (NAMS) position statement states that laboratory testing is not required for diagnosis.

Testing is indicated in these specific situations:

| Situation | Tests to Order | |---|---| | Age under 45 years | FSH, estradiol, pregnancy test, TSH, prolactin | | Age under 40 years (POI evaluation) | FSH x2 (4-6 weeks apart), estradiol, karyotype, FMR1 premutation screen, adrenal antibodies | | On combined hormonal contraception or hormonal IUD | FSH (drawn during the hormone-free interval if applicable) | | Surgical history obscuring cycle data | FSH, estradiol | | Atypical symptom constellation | TSH, prolactin, beta-hCG, cortisol as indicated |

Interpreting FSH and Estradiol

FSH rises as ovarian reserve declines. A level above 40 IU/L, confirmed on a second draw 4 to 6 weeks later, is supportive of menopause or POI depending on age Webber et al., 2016, Fertility and Sterility. FSH can fluctuate significantly in perimenopause, so a single elevated reading is not diagnostic.

Estradiol below 20 pg/mL is consistent with post-menopausal levels. However, in perimenopause, estradiol is often intermittently elevated (sometimes above premenopausal norms) before it eventually falls. A normal estradiol does not exclude perimenopause.

Anti-Mullerian hormone (AMH) declines with ovarian reserve and is sometimes used to predict the timing of menopause, but it is not a diagnostic test for menopause itself and is not part of standard guidelines.

Step 4: Apply Age-Specific and Life-Stage-Specific Pathways

The algorithm branches depending on your age and reproductive stage. This is where women's-health framing is essential, because a 38-year-old, a 48-year-old, and a 55-year-old with the same symptoms require different workups and different conversations.

Reproductive Years (Under 40): Premature Ovarian Insufficiency

If you are under 40 and your periods have stopped or become very irregular, the correct term is premature ovarian insufficiency (POI), not "early menopause." POI affects approximately 1% of women under 40 and carries specific implications for fertility, bone health, and cardiovascular disease that differ from natural menopause.

Diagnosis requires two FSH measurements above 40 IU/L, taken at least 4 weeks apart, in the context of at least 4 months of cycle irregularity. The evaluation also includes a karyotype (to detect Turner syndrome mosaicism), FMR1 premutation screening (fragile X carrier status), and adrenal antibody testing (to exclude autoimmune adrenal disease, which may co-occur).

Women with POI who want to conceive should be referred to a reproductive endocrinologist promptly. Spontaneous pregnancy occurs in approximately 5 to 10% of women with POI and cannot be reliably predicted, so contraception discussions are relevant even after diagnosis if pregnancy is not desired.

Hormone therapy for POI should continue at least until the natural age of menopause (approximately 51 years) to protect bone density and cardiovascular health.

Early Menopause (Ages 40 to 45)

Women in this range warrant the same laboratory evaluation as POI, with particular attention to thyroid function, prolactin, and hypothalamic causes. If no secondary cause is found and FSH confirms ovarian insufficiency, the clinical management resembles that of POI: hormone therapy is generally recommended for bone and cardiovascular protection, and fertility referral is appropriate if pregnancy is desired.

The Menopausal Transition (Ages 45 to 55, the Most Common Scenario)

This is the group for whom clinical diagnosis alone, without laboratory testing, is supported by guidelines. Your cycle has become irregular. Hot flashes wake you at 3 a.m. Your periods are heavier or lighter or simply erratic. You have gone 60 days without a period.

If you are in this age range and not on hormonal contraception, a clinical diagnosis of perimenopause or menopause (depending on how many months of amenorrhea have elapsed) is appropriate. If 12 months have passed since your last period, you are post-menopausal by definition.

If you are on a combined hormonal contraceptive, the pill, patch, or ring suppresses ovulation and produces withdrawal bleeds that do not reflect your true cycle. FSH testing is required to assess ovarian function, ideally drawn during the hormone-free interval.

Post-Menopause (Over 55 or 12 Months Past Last Period)

The diagnostic question has usually been settled. The clinical focus shifts to managing GSM, protecting bone mineral density, assessing cardiovascular risk, and revisiting whether hormone therapy (if started) should continue.

Any return of bleeding in this group requires urgent evaluation: transvaginal ultrasound to measure endometrial stripe thickness, with endometrial biopsy if the stripe is above 4 mm ACOG Practice Bulletin 128.

Step 5: Assess Cardiovascular, Bone, and Metabolic Risk

Diagnosis does not end at confirming menopause. A complete menopause assessment includes evaluating the organ systems most affected by estrogen loss.

Bone Health

Estrogen loss accelerates bone resorption. The 2 to 3 years around the final menstrual period see the steepest decline in bone mineral density Finkelstein et al., NEJM, 2008. The U.S. Preventive Services Task Force recommends screening for osteoporosis in women 65 and older with dual-energy X-ray absorptiometry (DXA), and in younger postmenopausal women whose 10-year fracture risk (calculated by FRAX) equals or exceeds that of a 65-year-old white woman with no risk factors.

Women with POI or early menopause should have a baseline DXA at diagnosis rather than waiting until 65.

Cardiovascular Risk

The menopausal transition is associated with adverse changes in lipid profile (LDL rises, HDL may fall), blood pressure, central adiposity, and insulin resistance. A baseline lipid panel, fasting glucose, and blood pressure measurement are reasonable at the time of diagnosis, particularly for women who have not had recent metabolic screening.

PCOS is worth flagging here. Women with PCOS already carry elevated baseline cardiometabolic risk and often experience earlier or more pronounced metabolic changes with menopause.

Metabolic Health and Weight

Many women gain weight during the menopausal transition. This reflects a redistribution of fat toward visceral depots more than an absolute increase in caloric intake. Estrogen loss drives this shift. GLP-1 receptor agonists are increasingly used in this context for women with obesity or metabolic disease, though trial data specific to postmenopausal women remain limited.

Step 6: Move Directly to a Treatment Decision

Diagnosis and treatment are not separate conversations to schedule weeks apart. Once menopause or perimenopause is confirmed, you and your clinician should begin discussing symptom burden and treatment options in the same visit.

Vasomotor Symptoms (Hot Flashes and Night Sweats)

Systemic hormone therapy (estrogen, with progestogen added for women with a uterus) is the most effective treatment for moderate-to-severe VMS. The 2023 Menopause Society position statement states that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks.

For women who cannot or prefer not to use hormone therapy, options include:

• Fezolinetant (Veozah), a neurokinin B receptor antagonist approved by the FDA in 2023 specifically for moderate-to-severe VMS in menopause. In the SKYLIGHT 4 trial, fezolinetant 45 mg daily reduced hot flash frequency by approximately 60% versus 35% for placebo at 12 weeks.
• Paroxetine 7.5 mg (Brisdelle), the only FDA-approved non-hormonal option prior to fezolinetant.
• Venlafaxine, gabapentin, and clonidine carry evidence for VMS reduction but are off-label.

Genitourinary Syndrome of Menopause (GSM)

GSM encompasses vaginal dryness, dyspareunia, and urinary symptoms from local estrogen deficiency. It does not improve without treatment and often worsens over time. Vaginal (local) estrogen, ospemifene (an oral SERM), or the vaginal DHEA product prasterone are first-line options. Local vaginal estrogen has minimal systemic absorption and is generally safe even in women with contraindications to systemic hormone therapy.

WomanRx Diagnostic-to-Treatment Bridge Framework: Rather than treating diagnosis and management as sequential steps, use this simultaneous two-track approach at the first menopause-focused visit:

• Track 1 (Confirm): Establish life stage using STRAW+10 criteria, obtain targeted labs only if age or clinical context requires them, and document the date of last menstrual period precisely.
• Track 2 (Treat): Assess VMS severity using the Hot Flash Related Daily Interference Scale (HFRDIS), screen for GSM symptoms, order baseline bone and metabolic labs, and initiate treatment discussion before the patient leaves.

This framework is supported by the Menopause Society's 2023 clinical guidance, which explicitly discourages deferring symptom management pending diagnostic certainty in women over 45 with classic presentations.

Who This Diagnosis Pathway Is Right For, and Who Needs a Different Route

Right for This Algorithm

• Women aged 45 to 55 with cycle irregularity, VMS, and no red-flag symptoms
• Women over 55 confirming post-menopausal status
• Women with POI or early menopause who need the expanded workup described in Step 4

Requires Modification or Specialist Referral

• Women on tamoxifen or aromatase inhibitors for breast cancer (the menopausal transition is altered; hormone therapy decisions require oncology input)
• Women with premature ovarian insufficiency who want to conceive
• Women with postmenopausal bleeding (endometrial evaluation first)
• Women with significant cardiovascular disease where systemic hormone therapy timing and route require specialist co-management
• Women with a history of hormone-sensitive cancer (breast, endometrial) where hormone therapy may be contraindicated or requires individualized risk-benefit analysis

Pregnancy, Lactation, and Contraception Considerations

Perimenopause does not equal infertility. Spontaneous ovulation continues intermittently throughout the menopausal transition, and pregnancy remains possible until 12 months of amenorrhea are confirmed.

The ACOG recommends that perimenopausal women who do not want pregnancy use contraception until menopause is confirmed. Combined hormonal contraceptives (pill, patch, ring) are generally safe for non-smoking perimenopausal women without cardiovascular contraindications, and they have the added benefit of regulating cycle pattern and reducing VMS. Progestogen-only methods (mini-pill, hormonal IUD, implant, injectable) are alternatives with fewer estrogen-related risks.

Women who are confirmed post-menopausal do not require contraception.

Systemic hormone therapy prescribed for menopausal symptoms is not contraceptive. The doses of estrogen used in standard hormone therapy formulations (typically 0.5 to 1 mg oral estradiol or 0.025 to 0.05 mg transdermal estradiol) are lower than those in contraceptives and do not reliably suppress ovulation.

Regarding hormone therapy in pregnancy: systemic hormone therapy is not used in pregnancy. If a perimenopausal woman on hormone therapy becomes pregnant, therapy should be stopped and obstetric care initiated. Fezolinetant is contraindicated in pregnancy and requires a negative pregnancy test before initiation in women who retain any possibility of conception.

Vaginal estrogen (local, low-dose) is generally not recommended in pregnancy due to absence of safety data, though systemic absorption is minimal.

For lactating women who have returned to breastfeeding after a pregnancy that occurred during perimenopause: systemic estrogen may reduce milk supply. Local vaginal estrogen is sometimes used cautiously for severe GSM in breastfeeding women because systemic absorption is low, but this should be an individualized decision made with a knowledgeable clinician.

PCOS, Endometriosis, and Other Gynecologic Conditions in the Menopausal Transition

PCOS and Menopause

Women with PCOS often experience a later natural menopause than the general population, possibly reflecting a larger antral follicle pool at baseline. However, they carry a higher baseline risk for endometrial hyperplasia (from chronic anovulation and unopposed estrogen exposure), type 2 diabetes, and cardiovascular disease. These risks do not disappear at menopause. Ensure regular endometrial surveillance and aggressive metabolic monitoring in this group.

Endometriosis and Menopause

Endometriosis lesions are estrogen-dependent. Natural menopause usually reduces symptoms, but residual lesions may still respond to exogenous estrogen in post-menopausal hormone therapy. Women with a history of endometriosis who start hormone therapy after menopause typically require a combined estrogen-progestogen regimen (not estrogen alone) even after hysterectomy, to avoid reactivating residual disease. The Royal College of Obstetricians and Gynaecologists addresses this in their scientific impact paper on hormone therapy and endometriosis.

Fibroids

Fibroids are estrogen-sensitive and generally shrink after menopause. If a woman on hormone therapy notices fibroid regrowth or new uterine bleeding, the dose and route of estrogen should be reviewed.

The Evidence Gap: What We Know and What We Are Extrapolating

Women have been underrepresented in cardiovascular and metabolic trials, and the menopause-specific data picture is uneven. Here is what is directly studied versus extrapolated.

Directly studied in women:

• VMS frequency and severity with hormone therapy (extensive RCT data including the Women's Health Initiative, WHI, JAMA, 2002)
• Bone mineral density preservation with estrogen (multiple RCTs)
• Fezolinetant efficacy in VMS (SKYLIGHT 4, NEJM, 2023)
• GSM response to local estrogen, ospemifene, and prasterone

Extrapolated or limited data:

• Cardiovascular benefit of hormone therapy timing (the "timing hypothesis" or "window of opportunity" rests largely on observational data and sub-group analyses, not prospective RCTs designed around this question)
• GLP-1 agonist efficacy specifically in post-menopausal women (most trials enrolled mixed populations)
• Optimal hormone therapy regimens for women with POI (long-term RCT data are sparse; current recommendations are extrapolated from general menopause and contraceptive research)

The 2022 Hormone Therapy Position Statement of The Menopause Society explicitly acknowledges these gaps and uses a tiered evidence rating system. When your clinician recommends a course of action based on observational data rather than a randomized trial, that is worth knowing, and worth asking about.